Tumor suppressor genes

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Proteins, Tumor suppressor genes, Apoptosis, P53, Programmed cell death, Bert Vogelstein, Mdm2

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

Key Points: 
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • p53 mutations are found in approximately half of all cancers.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference

Retrieved on: 
Thursday, June 3, 2021
Branches of biology, Proteins, Cell biology, Biology, Tumor suppressor genes, Apoptosis, P53, Programmed cell death

A replay of the presentation will be available by visiting the Events & Presentations section of the PMV Pharmaceuticals website.

Key Points: 
  • A replay of the presentation will be available by visiting the Events & Presentations section of the PMV Pharmaceuticals website.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Global Team of Cancer Genetic Specialists Provides New Guidance for Individuals with PALB2 Gene Variants: ACMG Clinical Practice Resource to Help Guide Clinical Management of Patients at Increased Risk of Breast, Pancreatic and Ovarian Cancers

Retrieved on: 
Tuesday, May 11, 2021
Branches of biology, Breast cancer, Cancer, Tumor markers, Tumor suppressor genes, Genetics, Hereditary cancers, BRCA2, BRCA1, PALB2, Variant of uncertain significance, BRCA mutation

Germline pathogenic/likely pathogenic (P/LP) variants in PALB2 were first associated with increased cancer risk in 2007 and clinical testing has been available since then.

Key Points: 
  • Germline pathogenic/likely pathogenic (P/LP) variants in PALB2 were first associated with increased cancer risk in 2007 and clinical testing has been available since then.
  • It has come to be considered as the third most important breast cancer gene after BRCA1 and BRCA2.
  • While the range of the cancer risk estimates overlap with BRCA1/2, it is lower in PALB2, so individualized estimates are important for management decisions.
  • "First, it reflects a commitment of the ACMG to develop guidance for use of germline genetic information for the treatment of patients with cancer.

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

Retrieved on: 
Wednesday, May 5, 2021
Branches of biology, Proteins, Tumor suppressor genes, Cell biology, Biology, Apoptosis, P53, Programmed cell death

b'A replay of the presentation will be available by visiting the \xe2\x80\x9c Events & Presentations \xe2\x80\x9d section of the PMV Pharmaceuticals website.\nPMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

Key Points: 
  • b'A replay of the presentation will be available by visiting the \xe2\x80\x9c Events & Presentations \xe2\x80\x9d section of the PMV Pharmaceuticals website.\nPMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • p53 mutations are found in approximately half of all cancers.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.\xc2\xa0 PMV Pharma is headquartered in Cranbury, New Jersey.

InterVenn Biosciences Announces That Arnold Levine Has Joined the Company’s Board of Advisors

Retrieved on: 
Monday, May 3, 2021
Oncology, Health, Medical devices, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Tumor suppressor genes, Biology, Proteins, Carcinogenesis, P53, Programmed cell death, Arnold J. Levine, Tumor suppressor gene

b'InterVenn Biosciences today announced that Arnold Levine, Ph.D., has joined the Company\xe2\x80\x99s Board of Advisors, effective March 19, 2021.

Key Points: 
  • b'InterVenn Biosciences today announced that Arnold Levine, Ph.D., has joined the Company\xe2\x80\x99s Board of Advisors, effective March 19, 2021.
  • Dr. Levine joins the InterVenn Board of Advisors as one of the pioneers of molecular cancer research.\nDr.
  • Levine and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development.
  • For more information about InterVenn Biosciences, please visit the company\xe2\x80\x99s website .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210503005177/en/\n'

Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer

Retrieved on: 
Thursday, April 15, 2021
Branches of biology, Clinical medicine, Tumor suppressor genes, Medical genetics, Breast cancer, Tumor markers, BRCA2, Penetrance, P53, Genetic testing, Colorectal cancer, Cancer

In the study, 361 colorectal cancer patients received germline genetic testing using a panel that included more than 80 genes linked to increased cancer risk.

Key Points: 
  • In the study, 361 colorectal cancer patients received germline genetic testing using a panel that included more than 80 genes linked to increased cancer risk.
  • Cancer-linked genetic changes were found in 15.5% (n=56) of patients predominantly in moderate and high penetrance cancer susceptibility genes such as APC, BRCA2 and TP53.
  • Invitae\'s goal is to aggregate the world\'s genetic tests into a single service with higher quality, faster turnaround time, and lower prices.
  • These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.\n'

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

Retrieved on: 
Saturday, April 10, 2021
Branches of biology, Proteins, Cell biology, Biology, Apoptosis, Programmed cell death, Tumor suppressor genes, P53

"The preclinical data provide compelling evidence that PC14586 selectively reactivates the p53 Y220C mutant protein, both in vitro and in vivo, said David Mack, Ph.D., President and Chief Executive Officer of PMV.

Key Points: 
  • "The preclinical data provide compelling evidence that PC14586 selectively reactivates the p53 Y220C mutant protein, both in vitro and in vivo, said David Mack, Ph.D., President and Chief Executive Officer of PMV.
  • Oral presentation titled, PC14586: The First Orally Bioavailable Small Molecule Reactivator of Y220C Mutant p53 in Clinical Development presented by Melissa L. Dumble, Ph.D., Vice President Preclinical Development and Translational Science of PMV.
  • Mutant p53 takes on oncogenic properties that endow cancer cells with a growth advantage and resistance to anti-cancer therapy.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Clinical medicine, Proteins, Oncology, Tumor suppressor genes, Hereditary cancers, P53, Cancer, ATM serine/threonine kinase, Carcinogenesis, Neoplasm, Breast cancer

Mutant p53 takes on oncogenic properties that endow cancer cells with a growth advantage and resistance to anti-cancer therapy.

Key Points: 
  • Mutant p53 takes on oncogenic properties that endow cancer cells with a growth advantage and resistance to anti-cancer therapy.
  • The p53 Y220C mutation is associated with many cancers, including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic, and ovarian cancers.
  • PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Retrieved on: 
Wednesday, March 3, 2021
Branches of biology, Cell biology, Biology, Proteins, Apoptosis, Programmed cell death, Tumor suppressor genes, P53

The Phase 1/2 study will enroll up to 130 patients with a p53 Y220C mutation as determined by next generation sequencing.

Key Points: 
  • The Phase 1/2 study will enroll up to 130 patients with a p53 Y220C mutation as determined by next generation sequencing.
  • Phase 2 will assess the overall response rate and duration of response at the PC14586 dose identified in Phase 1.
  • PMV Pharma ended the fourth quarter with $361.4 million in cash, cash equivalents, and marketable securities, compared to $101.5 million as of December 31, 2019.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference

Retrieved on: 
Tuesday, February 23, 2021
Branches of biology, Proteins, Tumor suppressor genes, Cell biology, Biology, Apoptosis, P53, Programmed cell death, Bert Vogelstein, Mdm2

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

Key Points: 
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • p53 mutations are found in approximately half of all cancers.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.